Molecular patterns in deficient mismatch repair colorectal tumours: Results from a French prospective multicentric biological and genetic study

British Journal of Cancer

Volumn 110, Issue 11, 2014, Pages 2728-2737

  Etienne Grimaldi, M C ^a   Mahamat, A ^b   Chazal, M ^c   Laurent Puig, P ^d   Olschwang, S ^e   Gaub, M P ^f   Formento, J L ^a   Formento, P ^a   Sudaka, A ^a   Boige, V ^g   Abderrahim Ferkoune, A ^b   Benchimol, D ^b   Andre T ^h   Houry, S ^h   Faucheron, J L ⁱ   Letoublon, C ⁱ   Gilly, F N ^j   Delpero, J R ^k   Lasser, P ^g   Pradere, B ^l   Pezet, D ^m   Penault Llorca, F ⁿ   Milano, G ^a   more..

^a CENTRE ANTOINE LACASSAGNE   (France)

^b UNIVERSITY HOSPITAL OF NICE   (France)

^c Saint George Clinic   (France)

^d INSERM   (France)

^e TIMONE HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ GRENOBLE UNIVERSITY HOSPITAL   (France)

^j HOSPICES CIVILS DE LYON   (France)

^k INSTITUT PAOLI CALMETTES   (France)

^l TOULOUSE UNIVERSITY HOSPITAL   (France)

^m UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

ⁿ CENTRE JEAN PERRIN   (France)

more..

Author keywords

colorectal cancer; dihydropyrimidine dehydrogenase; fluoropyrimidine; gene expression; mismatch repair; thymidylate synthase

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; B RAF KINASE; DIHYDROPYRIMIDINE DEHYDROGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; K RAS PROTEIN; PIK3CA PROTEIN; PROTEIN P53; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE S PHASE; CODON; COLORECTAL TUMOR; CONTROLLED STUDY; CPG ISLAND; DISORDERS OF DNA SYNTHESIS AND REPAIR; DNA METHYLATION; DNA POLYMORPHISM; EXON; FEMALE; GENE EXPRESSION; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC MARKER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; MOLECULAR PATHOLOGY; MULTICENTER STUDY; PHENOTYPE; PLOIDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN CONTENT; PROTEIN EXPRESSION; RECEPTOR BINDING ASSAY; RECURRENCE FREE SURVIVAL; SURVIVAL PREDICTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); DISEASE-FREE SURVIVAL; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; FRANCE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84901596056     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.213     Document Type: Article

References (39)

1. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 90: 675-684.
2. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J,Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lövig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urosevic N (2001) Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 85: 692-696.
3. Beck A, Etienne MC, Chéradame S, Fischel JL, Formento P, Renée N, Milano G (1994) A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 30A: 1517-1522.
4. Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS (2011) Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer-a study of CALGB 9581 and 89803. J Clin Oncol 29: 3153-3162.
5. Burrell RA, McClelland SE, Endesfelder D, Groth P, Weller MC, Shaikh N, Domingo E, Kanu N, Dewhurst SM, Gronroos E, Chew SK, Rowan AJ, Schenk A, Sheffer M, Howell M, Kschischo M, Behrens A, Helleday T, Bartek J, Tomlinson IP, Swanton C (2013) Replication stress links structural and numerical cancer chromosomal instability. Nature 494: 492-496.
6. Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337.
7. Eklöf V, Wikberg ML, Edin S, Dahlin AM, Jonsson BA, Ö berg Å, Rutegård J, Palmqvist R (2013) The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer 108: 2153-2163.
8. Etienne MC, Pivot X, Formento JL, Bensadoun RJ, Formento P, Dassonville O, Francoual M, Poissonnet G, Fontana X, Schneider M, Demard F, Milano G (1999) A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Br J Cancer 79: 1864-1869.
9. Etienne MC, Chazal M, Laurent-Puig P, Magné N, Rosty C, Formento JL, Francoual M, Formento P, Renée N, Chamorey E, Bourgeon A, Seitz JF, Delpero JR, Letoublon C, Pezet D, Milano G (2002) Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 20: 2832-2843.
10. Etienne-Grimaldi MC, Cayre A, Penault-Llorca F, Francoual M, Formento JL, Benchimol D, Bourgeon A, Milano G (2006) EGFR expression in colon cancer: a break in the clouds. Ann Oncol 17(12): 1850-1851.
11. Gavin PG, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY, Yothers G, Kim C, Taniyama Y, Kim SI, Choi HJ, Blackmon NL, Lipchik C, Petrelli NJ, O'Connell MJ, Wolmark N, Paik S, Pogue-Geile KL (2012) Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 18: 6531-6541.
12. Grady WM, Carethers JM (2008) Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135: 1079-1099.
13. Gustavsson B, Kaiser C, Carlsson G, Wettergren Y, Odin E, Lindskog EB, Niyikiza C, Ma D (2009) Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes. Int J Cancer 124: 1220-1226.
14. Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M, Kerr D, Gray R, Quirke P (2011) Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29: 1261-1270.
15. Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, Nosho K, Qian ZR, Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S (2012) Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 18: 2257-2268.
16. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, Qian ZR, Morikawa T, Shen J, Meyerhardt JA, Fuchs CS, Ogino S (2013) Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 105: 1151-1156.
17. Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338.
18. Magné N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P, Milano G (2002) Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). Br J Cancer 86(9): 1518-1523.
19. Merok MA, Ahlquist T, Røyrvik EC, Tufteland KF, Hektoen M, Sjo OH, Mala T, Svindland A, Lothe RA, Nesbakken A (2013) Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Ann Oncol 24: 1274-1282.
20. Missiaglia E, Jacobs B, Di Narzo FA, Soneson C, Roth A, Bosman F, D'Ario G, Klingbiel D, Yan P, Delorenzi M, Tejpar S (2013) Proximal and distal colon tumours as distinct biologic entities with different prognoses. J Clin Oncol 31(suppl): abstr 3526.
21. Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson 3rd AB, Goldberg RM, Bertagnolli MM, Fuchs CS. Cancer and Leukemia Group B; North Central Cancer Treatment Group; Canadian Cancer Society Research Institute; Southwest Oncology Group (2009a) KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 15: 7322-7329.
22. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS (2009b) CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58: 90-96.
23. Onesto C, Hannoun-Lévi JM, Chamorey E, Formento JL, Ramaioli A, Pagès G (2006) Vascular endothelial growth factor-A and Poly(A) binding protein-interacting protein 2 expression in human head and neck carcinomas: correlation and prognostic significance. Br J Cancer 94: 1516-1523.
24. Popat S, Matakidou A, Houlston RS (2004) Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22: 529-536.
25. Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 23: 609-618.
26. Popovici VC, Budinska E, Roth A, Bosman F, Tejpar S, Delorenzi M (2013) BRAF and KRAS mutations as additional risk factors in the context of clinical parameters of patients with colorectal cancer. J Clin Oncol 31(suppl): abstr 3522.
27. Quasar Collaborative GroupGray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370: 2020-2029.
28. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247-257.
29. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P (2009) KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27: 5931-5937.
30. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28: 466-474.
31. Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, d'Ario G, Cisar L, Labianca R, Cunningham D, Nordlinger B, Bosman F, Van Cutsem E (2012) Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 104: 1635-1646.
32. Santini J, Formento JL, Francoual M, Milano G, Schneider M, Dassonville O, Demard F (1991) Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13: 132-139.
33. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28: 3219-3226.
34. Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ (2011) DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 103: 863-875.
35. Sinicrope FA, Sargent DJ (2012) Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res 18: 1506-1512.
36. Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR (2013) Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol 31: 3664-3672.
37. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA (2009) Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 101: 465-472.
38. Ueno H, Mochizuki H, Akagi Y, Kusumi T, Yamada K, Ikegami M, Kawachi H, Kameoka S, Ohkura Y, Masaki T, Kushima R, Takahashi K, Ajioka Y, Hase K, Ochiai A, Wada R, Iwaya K, Shimazaki H, Nakamura T, Sugihara K (2012) Optimal colorectal cancer staging criteria in TNM classification. J Clin Oncol 30: 1519-1526.
39. Van Schaeybroeck S, Allen WL, Turkington RC, Johnston PG (2011) Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol 8: 222-232.